Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?

Yamamoto, Michele; Pop-Vicas, Aurora

doi:10.1186/cc13949

Cited by 49 publications

(38 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The worldwide spread of CRE has become a major challenge (Yamamoto and Pop-Vicas, 2014). Unfortunately, the antibiotics available for clinicians for treating CRE infections are really very few.…”

Section: Issn: 2319-7706 Volume 7 Number 04 (2018)mentioning

confidence: 99%

Prevalence of Carbapenem Resistant Klebsiella and Proteus Clinical Isolates: A Real Threat to the Egyptian Health Care System

Fanaki¹,

Omar²,

Khalil³

et al. 2018

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Issn: 2319-7706 Volume 7 Number 04 (2018)mentioning

confidence: 99%

Prevalence of Carbapenem Resistant Klebsiella and Proteus Clinical Isolates: A Real Threat to the Egyptian Health Care System

Fanaki¹,

Omar²,

Khalil³

et al. 2018

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…Besides this, we can prevent the spread of micro-organisms through the hospital by rational use of antibiotics and taking infection control measures. 7,8 We aimed to determine risk factors and mortality in patients infected with CRKP by comparing with a control group.…”

Section: Introductionmentioning

confidence: 99%

Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumoniae infection: case control study

Akgül

Bozkurt

Sünbül

et al. 2016

Pathogens and Global Health

View full text Add to dashboard Cite

Carbapenem-resistant Klebsiella pneumoniae (CRKP) has been known as a nosocomial pathogen, both for the last 10 years in Turkey and for 20 years worldwide. Due to limited treatment options and high mortality rates, despite improvements in the field of medicine at the present time, CRKP is still a big threat for public health. This study was carried out between the dates of January 2010 and September 2014. Patients ≥18 who were hospitalized for at least 72 h and who also had CRKP growth were included in the study as a case group. In the same period patients, who were hospitalized in the same ward and did not have CRKP growth were selected as the control group. It was determined that no glycopeptides and steroids use nor tracheostomy as protective factors would be employed in terms of non-development of CRKP. Mechanical ventilation, tracheostomy, urinary catheter presence, central venous catheterization, nasogastric tube placement, advanced age, acute renal insufficiency, total parenteral nutrition, carbapenem, glycopeptide, and piperacillin tazobactam were all detected as risk factors in terms of CRKP infection development. As a result, rational usage of antibiotics for preventing infections developing with CRKP should be targeted.

show abstract

“…This is the first assay that combines all major ESBL, AmpC and carbapenemase genes into a two-tube assay, enabling the simultaneous detection of 14 of the most important markers of resistance to 3 rd generation cephalosporins and carbapenems. Carbapenemase carriage is increasing worldwide, and carriers are typically multidrug resistant, limiting the treatment options and often involving polymyxins or tigecycline 45 . Resistance to these latter drugs however is also emerging 46 .…”

Section: Discussionmentioning

confidence: 99%

A highly multiplexed melt-curve assay for detecting the most prevalent carbapenemase, ESBL and AmpC genes

Edwards

Williams

Teethaisong

et al. 2019

Preprint

View full text Add to dashboard Cite

AbstractResistance to third generation cephalosporins and carbapenems in Gram-negative bacteria is chiefly mediated by beta-lactamases including ESBL, AmpC and carbapenemase enzymes. Routine phenotypic detection methods do not provide timely results, and there is a lack of comprehensive molecular panels covering all important markers.An ESBL/carbapenemase HRM assay (SHV, TEM, CTX-M ESBLs, and NDM, IMP, KPC, VIM and OXA-48-like carbapenemases) and an AmpC HRM assay (16S rDNA control, FOX, MOX, ACC, EBC, CIT and DHA) were designed, and evaluated on 111 Gram-negative isolates with mixed resistance patterns.The sensitivity for carbapenemase, ESBL and AmpC genes was 96.7% (95%CI:82.8-99.9%), 93.6% (95%CI:85.7-97.9%) and 93.8% (95%CI:82.8-98.7%), respectively with a specificity of 100% (95%CI:95.6-100%), 93.9% (95%CI:79.8-99.3%) and 93.7% (95%CI:84.5-98.2%).The HRM assays enable the simultaneous detection of the fourteen most important ESBL, carbapenemase and AmpC genes and could be used as a molecular surveillance tool or to hasten detection of AMR for treatment management.

show abstract

Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?

Cited by 49 publications

References 57 publications

Prevalence of Carbapenem Resistant Klebsiella and Proteus Clinical Isolates: A Real Threat to the Egyptian Health Care System

Prevalence of Carbapenem Resistant Klebsiella and Proteus Clinical Isolates: A Real Threat to the Egyptian Health Care System

Risk factors and mortality in the Carbapenem-resistant Klebsiella pneumoniae infection: case control study

A highly multiplexed melt-curve assay for detecting the most prevalent carbapenemase, ESBL and AmpC genes

Contact Info

Product

Resources

About